These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 2460511)
1. MR characteristics of prostatic carcinoma and benign prostatic hyperplasia at 1.5 T. Griebel J; Hess CF; Schmiedl U; Koelbel G J Comput Assist Tomogr; 1988; 12(6):988-94. PubMed ID: 2460511 [TBL] [Abstract][Full Text] [Related]
2. Differentiation of prostate cancer from benign prostate hypertrophy using dual-echo dynamic contrast MR imaging. Muramoto S; Uematsu H; Kimura H; Ishimori Y; Sadato N; Oyama N; Matsuda T; Kawamura Y; Yonekura Y; Okada K; Itoh H Eur J Radiol; 2002 Oct; 44(1):52-8. PubMed ID: 12350413 [TBL] [Abstract][Full Text] [Related]
3. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Kurhanewicz J; Vigneron DB; Nelson SJ; Hricak H; MacDonald JM; Konety B; Narayan P Urology; 1995 Mar; 45(3):459-66. PubMed ID: 7533458 [TBL] [Abstract][Full Text] [Related]
4. Prostatic carcinoma and benign prostatic hyperplasia: inability of MR imaging to distinguish between the two diseases. Ling D; Lee JK; Heiken JP; Balfe DM; Glazer HS; McClennan BL Radiology; 1986 Jan; 158(1):103-7. PubMed ID: 2416005 [TBL] [Abstract][Full Text] [Related]
6. [Magnetic resonance imaging in the diagnosis of prostatic carcinoma and benign hyperplasia]. Fujiwara K; Isaka S; Shimazaki J Nihon Hinyokika Gakkai Zasshi; 1989 Sep; 80(9):1336-42. PubMed ID: 2480470 [TBL] [Abstract][Full Text] [Related]
7. Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. Schiebler ML; Tomaszewski JE; Bezzi M; Pollack HM; Kressel HY; Cohen EK; Altman HG; Gefter WB; Wein AJ; Axel L Radiology; 1989 Jul; 172(1):131-7. PubMed ID: 2472644 [TBL] [Abstract][Full Text] [Related]
8. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. García-Segura JM; Sánchez-Chapado M; Ibarburen C; Viaño J; Angulo JC; González J; Rodríguez-Vallejo JM Magn Reson Imaging; 1999 Jun; 17(5):755-65. PubMed ID: 10372529 [TBL] [Abstract][Full Text] [Related]
9. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Kurhanewicz J; Vigneron DB; Hricak H; Narayan P; Carroll P; Nelson SJ Radiology; 1996 Mar; 198(3):795-805. PubMed ID: 8628874 [TBL] [Abstract][Full Text] [Related]
10. The value of ESWAN in diagnosis and differential diagnosis of prostate cancer: Preliminary study. Xin JY; Gao SS; Liu JG; Sun CF; Han Y; Sun XH; Wang XZ; Wang B Magn Reson Imaging; 2017 Dec; 44():26-31. PubMed ID: 28782677 [TBL] [Abstract][Full Text] [Related]
11. Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MR imaging and histopathology. Turnbull LW; Buckley DL; Turnbull LS; Liney GP; Knowles AJ J Magn Reson Imaging; 1999 Feb; 9(2):311-6. PubMed ID: 10077030 [TBL] [Abstract][Full Text] [Related]
12. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH. Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158 [TBL] [Abstract][Full Text] [Related]
13. Clinical Value of Magnetic Resonance Imaging Combined With Serum Prostate-specific Antigen, Epithelial Cadherin and Early Prostate Cancer Antigen 2 In Diagnosis of Prostate Cancer. Li K; Luan Q; Zheng J; Li R; Li L; Sun Y; Liu D Anticancer Res; 2023 Jan; 43(1):441-447. PubMed ID: 36585192 [TBL] [Abstract][Full Text] [Related]
14. [Anatomy and sonography of the prostate]. Hammerer P; Huland H Urologe A; 1989 Nov; 28(6):311-6. PubMed ID: 2481356 [TBL] [Abstract][Full Text] [Related]